

Special Issue

Biological Aspects of Drug Addiction 2.0

Message from the Guest Editors

Drug addiction represents an important socioeconomic and health burden worldwide. Biological aspects of drug addiction involve more than a "vulnerable" or a "drug-sculpted" brain. Alterations in physiological systems are common in individuals with substance use disorders and may also be associated with the severity of the addictive disorder and/or vulnerability to drug use. In fact, substance use disorder is frequently associated with comorbid psychiatric disorders (such as mood disorders, anxiety, eating disorders and other substance use disorders) or other comorbid medical diseases (such as cancer, liver diseases and pancreatitis). This Special Issue will focus on the biological aspects of drug addiction in a broad sense, including genetics, biochemical, physiological, functional and structural correlates found in the brain and also peripheral body tissues and organs. Understanding the biological basis of drug addiction will provide valuable opportunities for its prevention, diagnosis and treatment, since biological variables may serve as both biomarkers and therapeutic targets for the disease.

Guest Editors

Prof. Dr. Gabriel Rubio

Hospital Universitario 12 de Octubre, Madrid, Spain

Dr. Laura Orio

Department of Psychobiology and Behavioral Sciences Methods,
Faculty of Psychology, Complutense University of Madrid (UCM),
Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/132642

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).